Abstract
Epstein-Barr virus-positive diffuse large B-cell lymphoma (EBV+ DLBCL) in pediatrics most commonly occurs as an iatrogenic immunodeficiency-associated lymphoproliferative disease. We report an 18-year-old female individual with refractory systemic juvenile idiopathic arthritis, treated with multiple immunosuppressive agents, who was diagnosed with stage III, EBV+ DLBCL. The patient achieved sustained complete remission after 4 weekly doses of rituximab monotherapy and reduction of immunosuppression. This case suggests that a post-transplant lymphoproliferative disease-like treatment approach can be a safe and effective therapy in a nontransplant, yet severely immunosuppressed, patient with EBV+ DLBCL.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E498-E500 |
| Journal | Journal of pediatric hematology/oncology |
| Volume | 43 |
| Issue number | 4 |
| DOIs | |
| State | Published - May 2021 |
Bibliographical note
Publisher Copyright:© 2021 Lippincott Williams and Wilkins. All rights reserved.
Keywords
- Epstein-Barr virus
- diffuse large B-cell lymphoma
- immunosuppression
- juvenile idiopathic arthritis
- rituximab
PubMed: MeSH publication types
- Case Reports
- Journal Article
